Search Results

mutations have been found in this population ( Table 1 ). Typically, in those with RDD, BRAF mutations do not occur; however, MAPK pathway gene mutations are common. “Notably, [in] approximately 10% to 20% of cases, the mutations remain unknown,” Dr. Go

Clin Endocrinol Metab 2003 ; 88 : 1947 – 1960 . 20. Shchemelinin I Sefc L Necas E . Protein kinase inhibitors . Folia Biol (Praha) 2006 ; 52 : 137 – 148 . 21. Solit DB Garraway LA Pratilas CA . BRAF mutation predicts

best sensitivity and specificity to detect somatic BRAF mutations in papillary craniopharyngioma, we recommend an approach using DNA-based testing (such as PCR or NGS) and antibody-based testing (immunohistochemistry to detect mutant BRAF protein

the RAS/RAF/MEK/ERK pathway, a key oncogenic signaling cascade for many human malignancies. 3 Activating BRAF mutations are the most common cause for this activation in PTC, occurring in 25% to 49% of tumors. Moreover, the presence of this mutation

neck (1.4%–3%). 12 , 13 However, it is important to note that BRAF mutations are enriched in some variants of GBM, such as epithelioid GBM, a rare but recently recognized variant of IDH wild-type GBMs. 14 Although epithelioid GBMs often lack the

in 5% to 7%, ROS1 rearrangements in 1% to 3%, and BRAF mutations in 2% to 5%. “The best therapeutic outcome is seen if therapy is targeted to the first 3 mutations— EGFR , ALK , and ROS1 . It is critically important to perform testing for

characteristics, such as microsatellite instability-high (MSI-H), BRAF mutation, or HER2 overexpression. Hereditary risk assessment and screening are also essential components in caring for patients with intestinal cancers, since many are potentially preventable

develop studies to scientifically evaluate and define GSK2118436, a BRAF inhibitor, and GSK1120212, a MEK1 and MEK2 inhibitor. Previous research has indicated that BRAF mutations are strong targets for therapies in the treatment of advanced melanoma

: Determine the objective response rate of the combination sorafenib and temsirolimus in I-131 refractory thyroid cancer Secondary Outcome Measures: Evaluate if the presence of BRAF mutations, with or without concomitant mutations in the PI3K AKT, mTOR

rate of combination sorafenib and temsirolimus in I-131 refractory thyroid cancer Secondary Outcome Measures: Evaluate if the presence of BRAF mutations, with or without concomitant mutations in the PI3K AKT, mTOR pathway, predicts